Global Heparin Market Is Projected To Expand At ~5% CAGR By 2026

Heparin is utilized to make an anti-clotting surface inside a variety of medical devices, including test tubes and renal dialysis machines. The Global Heparin Market is expected to grow at a rate of ~5% by 2026. The rising prevalence of chronic diseases such as venous thromboembolism, pulmonary embolism, renal diseases, and cardiovascular disorders, the increasing geriatric population, high demand for anticoagulants, growing application of heparin in various surgeries such as orthopedic and heart surgeries, and the expanding availability of synthetic and semi-synthetic heparin mimetics that help in the treatment of cancer, coagulation, and inflammatory diseases are a few of the main factors driving the global heparin market.

Increasing Usage of Heparin in Various Applications Drives the Heparin Market

Anticoagulants work by decreasing the clotting ability of the blood. It helps to prevent the formation of clots as well as stop the further expansion of any existing clots. As a result, it may be used in a variety of applications, including:

• Prevent or treat certain blood vessel, heart, and lung conditions
• Prevent blood clotting during open-heart surgery, bypass surgery, kidney dialysis, and blood transfusions
• Prevention of deep vein thrombosis
• Prevention of a blood clot following percutaneous coronary intervention

Growing Adoption of Low Molecular Weight

The Growing Adoption of Low Molecular Weight Unfractionated Heparin Over Heparin to Prevent Deep Vein Thrombosis or Pulmonary Embolism Fuels the Demand.

Low-molecular-weight heparins have several advantages over UFH that have led to their increasing use for several thromboembolic indications such as deep vein thrombosis (DVT) and pulmonary embolism (PE) as well as atrial fibrillation (AF). In comparison to heparin, LMWH provides better bioavailability and a longer half-life, streamlined dose, predictable anticoagulant response, reduced risk of heparin-induced thrombocytopenia (HIT), and a reduced risk of osteoporosis.

Explore Premium Report on Heparin Market.

The Potential Role of Heparin in Covid-19 Patients Boosts the Heparin Market Growth

Many patients with COVID-19 develop clinically significant coagulopathy. COVID-19 infections can lead to an increased risk of blood clots. These blood clots can lead to individuals being admitted to hospital, or, unfortunately in severe cases, death. Similarly, patients with COVID-19 are at high risk for developing clinically significant large-vessel thrombosis. Thus, early usage of anticoagulation may reduce the risk of coagulopathy, microthrombus formation, and organ damage.

Key Challenges/ Constraints: Heparin Market

The main factors limiting the market’s growth are the side effects associated to the usage of heparin drugs and the availability of another anticoagulant on the market.

North America Holds the Largest Market Share but APAC is Set to Witness Strongest Growth

North America holds the largest market share of the heparin market followed by Europe and the Asia Pacific. This can be primarily attributed to the high burden of chronic diseases, the presence of advanced and robust healthcare infrastructure, increasing demand for heparin in various surgeries, and rising incidences of cardiovascular disorders in the region.

Companies Adopt both Organic & Inorganic Growth Strategies to Increase their Market Share

Players operating in the heparin market are adopting organic and inorganic growth strategies such as collaborations, acquisitions, and expansions to garner market share.

For instance,

• In February 2022, Techdow USA Inc. announced the launch of its Heparin Sodium Injection, USP in the United States market
• In January 2022, Ohio-based biotechnology company Optimvia Pharmaceuticals announced the development of a synthetic method for creating large quantities of heparin, which is used to make a common blood thinner at a reasonable price

Competitive Landscape Analysis of the Heparin Market

The global heparin market is marked by the presence of established key players such as Baxter International Inc., B. Braun Holding GmbH & Co. KG, Dr. Reddy’s Laboratories Ltd., and Fresenius SE & Co KGaA among others.

For More Detailed Insights, Contact Us.

About Medi-Tech Insights

Medi-Tech Insights is a healthcare-focused business research & insights firm. Our clients include Fortune 500 companies, blue-chip investors & hyper-growth start-ups. We have completed 100+ projects in Digital Health, Healthcare IT, Medical Technology, Medical Devices & Pharma Services.

Contact:

Ruta Halde

Associate, Medi-Tech Insights

+32 498 86 80 79

info@meditechinsights.com